ALGS Aligos Therapeutics Inc.

15.53
-0.03  -0%
Previous Close 15.56
Open 15.57
52 Week Low 12.82
52 Week High 37.5099
Market Cap $660,858,806
Shares 42,553,690
Float 19,068,806
Enterprise Value $419,462,262
Volume 346,111
Av. Daily Volume 291,300
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ALG-000184
Hepatitis B
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ALG-010133
Hepatitis B
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
ALG-055009
Nonalcoholic steatohepatitis (NASH)
Phase 1
Phase 1
Phase 1 trial to commence 1H 2021.
ALG-020572
Hepatitis B
Phase 1
Phase 1
Phase 1 trial to commence 2H 2021.

Latest News

  1. SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's second quarter 2021 financial results on Thursday, August 5, 2021 after the close of U.S. financial markets.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging…

    SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the company's second quarter 2021 financial results on Thursday, August 5, 2021 after the close of U.S. financial markets.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Such forward-looking statements are subject to substantial risks and uncertainties, many of which may be beyond Aligos' control and could cause Aligos' development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, the Registration Statement on Form S-1 filed with the SEC on June 28, 2021, and its future periodic reports to be filed with the SEC.   Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock at the same terms and conditions. All of the shares of common stock are being offered by Aligos. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately $83.6 million, excluding any exercise of the underwriters' option to purchase additional shares. The…

    SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the underwriters a 30-day option to purchase up to an additional 660,000 shares of common stock at the same terms and conditions. All of the shares of common stock are being offered by Aligos. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aligos, are expected to be approximately $83.6 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on July 6, 2021, subject to customary closing conditions.

    J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.

    A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on June 30, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at pmorgan.com or by telephone at (866) 803-9204, or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at , or from Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos s focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond Aligos' control. These statements include statements regarding the completion and timing of the closing of the public offering. These statements involve risks and uncertainties, including, without limitation, the uncertainties inherent in the drug development process, regulatory approval processes, and the challenges associated with manufacturing drug products, as well as risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties relating to Aligos' business in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, the preliminary prospectus for this offering included as part of the Registration Statement on Form S-1 related to the offering filed with the SEC on June 28, 2021, and its future periodic reports to be filed with the SEC. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock. All of the shares of common stock are being offered by Aligos. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering…

    SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock. All of the shares of common stock are being offered by Aligos. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.

    A registration statement relating to these securities has been filed with the Securities and Exchange Commission (SEC) but has not yet become effective. The offering is being made only by means of a prospectus, copies of which may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at or by telephone at (866) 803-9204, or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at , or from Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond Aligos' control. These statements include statements regarding the completion, timing and size of the proposed public offering. These statement involve risks and uncertainties, including, without limitation, the uncertainties inherent in the drug development process, regulatory approval processes, and the challenges associated with manufacturing drug products, as well as risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties relating to Aligos' business in general, see Aligos' Quarterly Report on Form 10-Q filed with the SEC on May 10, 2021, the preliminary prospectus for this offering included as part of the Registration Statement on Form S-1 related to the proposed offering filed with the SEC on June 28, 2021, and its future periodic reports to be filed with the SEC. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.



    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  4. -First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients
    -Presentations include nonclinical data from 3 other CHB programs

    SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that a poster describing preliminary data in healthy volunteers (HVs) from the ongoing Phase 1a/b multi-part umbrella clinical trial of Aligos' S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) compound ALG-010133 will be presented at the European Association for the Study…

    -First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients

    -Presentations include nonclinical data from 3 other CHB programs

    SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that a poster describing preliminary data in healthy volunteers (HVs) from the ongoing Phase 1a/b multi-part umbrella clinical trial of Aligos' S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) compound ALG-010133 will be presented at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2021 (ILC 2021). ILC 2021 is being held virtually on June 23-26, 2021.

    The company will also present four other posters at the meeting, which are detailed below and highlight nonclinical data from multiple drug classes within Aligos' chronic hepatitis B (CHB) portfolio: STOPS molecules, a novel capsid assembly modulator (CAM) candidate, and the company's lead small interfering RNA (siRNA) and antisense oligonucleotide (ASO) drug candidates. The posters are expected to be made available to conference registrants beginning June 23. The posters will be available subsequently on the "Scientific Presentation and Publications" page in the "Presentations" section of Aligos' website at www.aligos.com.

    "Our team continues to be highly productive in advancing our CHB portfolio," said Lawrence Blatt, Ph.D., MBA, Chairman and CEO of Aligos. "The determination of the STOPS mechanism of action and advancement of our STOPS lead candidate, ALG-010133, from healthy volunteers into chronic hepatitis B patients, along with our recent presentation of the safety, pharmacokinetic, and antiviral proof-of-concept data for our lead CAM candidate, ALG-000184, at the HBV-TAG 2021 conference, highlights our ability to identify and develop drugs with best-in-class potential. We plan to share additional emerging antiviral activity for our lead STOPS and CAM programs, each of which are currently being dosed in the second of up to 6 CHB cohorts, in the second half of this year. Additionally, these promising data that we presented at the HBV-TAG 2021 conference support our recent decision to accelerate advancement of our portfolio of drug candidates toward combination therapies in CHB. To this end, we plan to also initiate a clinical trial evaluating our lead antisense oligonucleotide ALG-020572 in the second half of this year followed by initiation of a clinical trial for our siRNA ALG-125755 in the first half of 2022. By suppressing viral replication with our CAM molecule ALG-000184 as well as utilizing several complementary mechanisms for suppressing the production of HBsAg (STOPS, ASO and siRNA), we hope to identify a regimen that can lead to higher rates of functional cure for patients living with CHB."

    Leonid Beigelman, Ph.D., President at Aligos, noted, "We are excited to share the progress of our HBV portfolio at the EASL meeting. The mechanism of action data for our STOPS molecule highlighted the potent effects this drug class appears to have in suppressing the production of HBsAg by blocking host molecular pathways. Similarly, the data with our lead siRNA drug candidate showed how potently this compound suppresses production of HBsAg by catalyzing the destruction of HBsAg mRNA. We believe these complementary mechanisms, along with our ASO program, will work together, potentially synergistically, to reduce HBsAg levels in CHB patients.

    Aligos' five ILC 2021 presentations, and their potential implications, are summarized below.

    ALG-010133: S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™)

    Poster number: 1004

    Title: Safety, Tolerability and Pharmacokinetics (PK) of Single and Multiple Doses of ALG-010133, an S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPSTM) for the Treatment of Chronic Hepatitis B

    Presenter: Ed Gane

    Summary: The poster details the initial safety and pharmacokinetics of single ascending doses (SAD) and multiple ascending doses (MAD) of ALG-010133 in healthy volunteers (HVs). These SAD and MAD studies constitute two parts of a three-part, multicenter, double-blind, randomized, placebo-controlled study - ALG-010133-101 (NCT04485663).

    ALG-010133 was generally safe and well tolerated in HVs when given as single and multiple (3 weekly) subcutaneous doses of up to 200 and 180 mg, respectively. No serious adverse events, adverse events leading to premature study drug discontinuation, nor concerning laboratory, ECG, vital sign or physical examination findings were reported. Injection site reactions (ISRs) were seen in 19% of ALG-010133-treated subjects. Based on the PK exposures achieved in HVs, we expect that weekly subcutaneous doses of 120 mg and higher will be evaluated in cohorts of CHB subjects in Part 3.

    These data formed the basis for the prior decision to initiate 12 weeks of ALG-010133 dosing in CHB subjects (Part 3). To potentially mitigate any ISRs in CHB subjects, use of topical steroids has been implemented as a prophylactic measure.

    Poster number: 1305

    Title: Mechanism of Action of Hepatitis B Virus S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS™) Molecules

    Presenter: Cheng Kao

    Summary: In HepG2.2.15 cells transfected with the STOPS molecule ALG-10000, the molecule reduced both intracellular and extracellular S-antigen levels. As the molecule did not significantly co-localize with or bind to S-antigen, we believe it likely acts through other host cellular factors to reduce S-antigen levels. Five host proteins, all of which have roles in RNA processing, translation, or protein folding/degradation and are believed to function in viral replication and infection, were found to bind to ALG-10000: SRSF1, HNRNPA2B1, GRP78, RPLP1, and RPLP2.

    These data suggest that STOPS have a complex mechanism of action involving interactions with host factors which play a role in RNA processing, protein translation/folding, and transportation of the S-antigen protein.

    Capsid Assembly Modulators (CAMs)

    Poster number: 1386

    Title: Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity

    Presenter: Yannick Debing

    Summary: As part of a strategy to develop multiple structurally diverse CAM candidates to inhibit HBV viral replication in CHB, the authors characterized ALG-000111, a novel Class II CAM candidate. In vitro,

    ALG-000111 demonstrated sub-nanomolar potency, sustained antiviral activity and significant HBV DNA knockdown. The compound's prodrug form, ALG-000286, showed strong in vivo antiviral activity in an AAV-HBV mouse model as measured by declines in HBV DNA.

    Further development of this candidate is warranted as part of a diverse CHB portfolio.



    Small Interfering Ribonucleic Acids (siRNA)

    Poster number: 1196

    Title: ALG-125755, A Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model

    Presenter: Jin Hong

    Summary: Aligos' lead siRNA candidate, ALG-125755, which targets the small open reading frame of the S-antigen transcript in HBV, was shown to knock down S-antigen by 1.5 log10 IU/mL 28 days after a single subcutaneous dose of 5 mg/kg in the AAV-HBV mouse model of HBV infection. This encouraging degree of S-antigen reduction in vivo is corroborated by its potency in vitro, where the candidate demonstrated 23.9 pM and 28.8 pM EC50 values in two different cell culture assays. The compound also demonstrated a favorable pharmacological profile in vitro in multiple other cell culture systems.

    Taken together, these data suggest that the compound is a potent agent with respect to S-antigen reduction and warrants further development as a potential therapeutic for chronic hepatitis B.

    Combination of Small Interfering RNA (siRNA) and Antisense Oligonucleotides (ASO)

    Poster number: 1257

    Title: Combination Drug Interactions of Hepatitis B Virus (HBV) Small Interfering RNA (siRNA) and Antisense Oligonucleotides (ASO) In Vitro and In Vivo

    Presenter: Hua Tan

    Summary: As ASOs and siRNAs utilize independent pathways to potentially reduce S-antigen levels, unconjugated forms of Aligos' siRNA candidate ALG-125755 and of Aligos' ASO candidate ALG-020572 were evaluated for any additive or synergistic effects with respect to S-antigen knockdown, both in vitro and in vivo.

    In vitro, in dual combinations with each other as well as with other anti-HBV agents such as nucleos(t)ide analogs (NA) and capsid assembly modulators (CAM), the siRNA or ASO candidate each demonstrated a range of additive to significantly synergistic effects, depending on the specific combination used. With one another, the siRNA and ASO candidates exhibited synergy in vitro.

    These in vitro effects were confirmed in an AAV-HBV mouse model of HBV infection, where the ASO and siRNA exhibited additive effects with respect to S-antigen knockdown when combined.

    Based on the results of these interaction studies, further study is warranted to identify the most strategic combinations of siRNA and ASO candidates in CHB.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including but not limited to statements regarding Aligos' plan to share additional emerging antiviral activity for its lead STOPS and CAM programs in the second half of 2021; Aligos' plan to accelerate advancement of its portfolio of drug candidates toward combination therapies in CHB which would include initiating clinical trials of its ASO, ALG-020572, in the second half of 2021 followed by initiation of clinical trials for its siRNA, ALG-125755, in the first half of 2022; Aligos' hope in identifying a regimen that can lead to higher rates of functional cure for patients living with CHB; Aligos' belief that the complementary mechanisms of its STOPS molecule and lead siRNA drug candidate, along with its ASO program, will work together, potentially synergistically, to effectively reduce HBsAg levels in CHB patients. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos' ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos' capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on Aligos' business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, as well as other documents Aligos files from time to time with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577

     



    Primary Logo

    View Full Article Hide Full Article
  5. -Five scientific posters to be presented at upcoming EASL ILC meeting
    - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clinical development in H2 2021 and H1 2022, respectively
    -Antiviral activity data from at least one cohort of CHB patients for ALG-010133 and ALG-000184 expected to be presented in H2 2021

    SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will…

    -Five scientific posters to be presented at upcoming EASL ILC meeting

    - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clinical development in H2 2021 and H1 2022, respectively

    -Antiviral activity data from at least one cohort of CHB patients for ALG-010133 and ALG-000184 expected to be presented in H2 2021

    SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will present five abstracts highlighting data from the company's chronic hepatitis B (CHB) therapeutic programs. The presentations will take place at the European Association for the Study of the Liver (EASL) Digital International Liver Congress™ 2021 (ILC 2021), which is being held virtually on June 23-26, 2021. Important information for these posters can be found below.   

    Additionally, the company today announced a CHB portfolio update to highlight the progress made with the four development programs. Aligos reported that both its capsid assembly modulator (CAM) drug candidate and the S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS™) molecule drug candidate have now completed Phase 1a studies in healthy volunteers and are currently being evaluated in CHB patients in Phase 1b studies. We expect to present preliminary data from these Phase 1b studies in H2 2021. Once Phase 1b studies are completed, we plan to advance these drug candidates into Phase 2 studies in H2 2022 to identify combination regimens that could potentially result in enhanced rates of functional cure. Following closely behind the STOPS and CAM programs, Aligos' antisense oligonucleotide (ASO) and small interfering RNA (siRNA) drug candidates continue to advance through nonclinical development and are on track to start Phase 1 trials in H2 2021, and H1 2022, respectively.  For additional details, see the Chronic Hepatitis B Portfolio Summary below.

    ------------------------------------------

    Aligos' upcoming poster presentations at EASL's ILC 2021 are summarized below.   

    S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS™)

    Poster number: 1305

    Title: Mechanism of Action of Hepatitis B Virus S-antigen Transport-Inhibiting Oligonucleotide Polymers (STOPS™) Molecules

    Presenter: Cheng Kao

    Poster number: 1004

    Title: Safety, Tolerability and Pharmacokinetics (PK) of Single and Multiple Doses of ALG-010133, an S-Antigen Transport Inhibiting Oligonucleotide Polymer (STOPS™) for the Treatment of Chronic Hepatitis B

    Presenter: Ed Gane

    Capsid Assembly Modulators (CAMs)

    Poster number: 1386

    Title: Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity

    Presenter: Yannick Debing

    Small Interfering Ribonucleic Acids (siRNA)

    Poster number: 1196

    Title: ALG-125755, A Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model

    Presenter: Jin Hong

    Combination of Small Interfering RNA (siRNA) and Antisense Oligonucleotides (ASO)

    Poster number: 1257

    Title: Combination Drug Interactions of Hepatitis B Virus (HBV) Small Interfering RNA (siRNA) and Antisense Oligonucleotides (ASO) In Vitro and In Vivo

    Presenter: Hua Tan

    These posters will be available on demand to conference attendees throughout the conference. They will also be available on the "Scientific Presentation and Publications" page in the "Presentations" section of Aligos' website at www.aligos.com shortly after they are presented at the conference.   

    ------------------------------------------

    Chronic Hepatitis B Portfolio Summary

    ALG-010133 (STOPS) and ALG-000184 (CAM)

    ALG-010133 and ALG-000184 are each being evaluated in separate Phase 1 trials (NCT04485663 and NCT04536337) that include an evaluation in healthy volunteers (Phase 1a) followed by an evaluation in CHB patients (Phase 1b). The healthy volunteer portions of each study have been completed and the company is evaluating the drug candidates in CHB patients in both trials. In the case of the STOPS candidate, accomplishing at least a 1.0 log10 IU/mL mean reduction in HBV S-antigen levels after 12 weeks of weekly dosing is the targeted level of antiviral activity considered necessary to move into Phase 2 development. For the CAM drug candidate, preliminary antiviral activity data in treatment naïve (not previously treated) CHB subjects were promising, showing a mean HBV DNA reduction of 2.9 log10 IU/mL at Day 14 (Gane et al., HBV TAG 2021) and the drug was well tolerated. Data from patient cohorts for each drug candidate are planned for presentation at an upcoming medical conference in late 2021.   

    ALG-020572 (ASO)

    Aligos is developing ALG-020572, an ASO candidate that contains nucleotide stabilization chemistry in-licensed from Luxna Biotech Inc., Ltd. The company has nearly completed Phase 1 enabling nonclinical studies and has identified a lead candidate, which has demonstrated greater HBV S-antigen reduction compared to another known ASO drug candidate in clinical development in the HBV-AAV mouse model. The company plans to advance ALG-020572 into Phase 1 clinical studies in H2 2021.

    ALG-125755 (siRNA)

    Similarly, Aligos is developing ALG-125755, a novel siRNA using proprietary chemistry.    In nonclinical studies, ALG-125755 demonstrated greater HBsAg reductions compared to another known drug candidate in clinical development in the HBV-AAV mouse model. Aligos plans to advance its lead clinical candidate into the clinic in H1 2022.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including but not limited to statements regarding our expectation to present preliminary data from the Phase 1b studies of our CAM drug candidate and the STOPS™ molecule drug candidate in H2 2021; our plan, once Phase 1b studies are completed, to advance these drug candidates into Phase 2 studies in H2 2022; our ASO and siRNA drug candidates being on track to start Phase 1 trials in the second half of 2021, and the first half of 2022, respectively; our planned presentation of data from patient cohorts for each of the CAM and STOPS drug candidate at an upcoming medical conference in late 2021; our plans to advance ALG-020572 into clinical studies in the second half of 2021; and our plans to advance ALG-125755 into the clinic in the first half of 2022.    Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2021, as well as other documents Aligos files from time to time with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    aj

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577

     



    Primary Logo

    View Full Article Hide Full Article
View All Aligos Therapeutics Inc. News